Skip to content

A Study Evaluating Efruxifermin in Subjects With Compensated Cirrhosis Due to NASH/MASH

NASH - Nonalcoholic Steatohepatitis | MASH - Metabolic Dysfunction-Associated Steatohepatitis

This is a multi-center evaluation of efruxifermin (EFX) in a randomized, double-blind, placebo-controlled study in subjects with compensated cirrhosis due to NASH/MASH.

null

Conditions de participation

  • Sexe:

    ALL

  • Âges admissibles:

    18 to 80

Critères de participation

Inclusion Criteria:

* Cohort 1: Biopsy proven compensated cirrhosis (fibrosis stage 4) due to NASH/MASH
* Cohort 2: Biopsy proven or non-invasively diagnosed compensated cirrhosis (fibrosis stage 4) due to NASH/MASH

Exclusion Criteria:

* Other causes of liver disease based on medical history and/or liver histology and/or central laboratory results
* Type 1 diabetes or unstable Type 2 diabetes
* Any current or prior history of decompensated liver disease

Other inclusion and exclusion criteria may apply

Lieu de l'étude

Akero Clinical Study Site
Akero Clinical Study Site
Vaughan, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Akero Site 0504

Akero Clinical Study Site
Akero Clinical Study Site
Edmonton, Alberta
Canada

Contactez l'équipe d'étude

Primary Contact

Akero Site 0501

Akero Clinical Study Site
Akero Clinical Study Site
Toronto, Ontario
Canada

Contactez l'équipe d'étude

Primary Contact

Akero Site 0502

Étude parrainée par
Akero Therapeutics, Inc
Participants recherchés
Plus d'informations
ID de l'étude: NCT06528314